Press Release

RBCC: NASA Bioreactor Could Speed Parkinson’s Research

Stem cell research may hold the key to a cure for Parkinson’s disease.
The only problem is, stem cell research hasn’t advanced as quickly as
patients need it to. Rainbow BioSciences, the biotech subsidiary of
Rainbow Coral Corp. (OTCBB: RBCC) is working to market an advanced stem
cell growth solution that could potentially energize the worldwide
search for a cure.

Currently, government restrictions and ethical dilemmas serve as
roadblocks to fast-paced stem cell research, but even when these
roadblocks are absent, controlling the behavior of stem cells in a
laboratory isn’t easy. One way to help speed research projects up and
make them more efficient is to raise the number of high-quality adult
stem cells available for that research.

RBCC is working to do just that. The company has engaged Regenetech in
discussions regarding the potential acquisition of a license to perform
cell expansion using that company’s Rotary Cell Culture SystemTM.

Originally developed by NASA, the Rotary Cell Culture SystemTM is
a rotating-wall bioreactor designed to facilitate the growth of human
cells in simulated weightlessness. Cell cultures, including stem cells,
grown inside the bioreactor look and function much closer to human cells
grown within the body than the flat cell cultures grown in Petri dishes.

By bringing the bioreactor to emerging research markets where stem cell
research faces fewer roadblocks, RBCC hopes to help kickstart billions
of dollars worth of research into possible cures for Parkinson’s and
other neurological disorders.

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral
Corp. (OTCBB: RBCC). The company continually seeks out new partnerships
with biotechnology developers to deliver profitable new medical
technologies and innovations. For more information on our
growth-oriented business initiatives, please visit our website at [http://www.RainbowBioSciences.com].
For investment information and performance data on the company, please
visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act
of 1995: This news release contains forward-looking information within
the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
including statements that include the words "believes," "expects,"
"anticipate" or similar expressions. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that
may cause the actual results, performance or achievements of the company
to differ materially from those expressed or implied by such
forward-looking statements. In addition, description of anyone's past
success, either financial or strategic, is no guarantee of future
success. This news release speaks as of the date first set forth above
and the company assumes no responsibility to update the information
included herein for events occurring after the date hereof.

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her
physician.